Inside the ICE House
Inside the ICE House, a podcast produced by Intercontinental Exchange, takes listeners behind the historic façade of the New York Stock Exchange and inside the global financial marketplace. The episodes, recorded in the Library of the NYSE, features conversations with leaders, entrepreneurs and visionaries who walk through our doors with a dream of building businesses and changing the world. Their stories have made the NYSE, now part of ICE’s ecosystem of markets, clearing houses, data provider, and listings services, an indispensable institution for over 225 years.
Show episodes
Eric Criscuolo, Market Strategist at the NYSE, recaps a week of mixed equity performance, with AI and semiconductor stocks leading while Apple lagged. Labor data revisions and rising jobless claims signaled a softer job market, raising Fed policy questions. Inflation data was mixed, with PPI cooling but CPI still eleva
Biotech Series: Enveda CEO Viswa Colluru on the Mission to Decode Nature's Pharmacy
Enveda Biosciences is using AI to decode nature’s vast chemical library and transform it into breakthrough medicines. Founded in 2019 by Viswa Colluru, the company is advancing first-in-class therapies like ENV-294 while cutting the time and cost of drug discovery. Colluru joins Inside the ICE House to share how Enveda
Biotech Series: Nimbus CEO Abbas Kazimi on Leading the Future of Precision Therapeutics
Nimbus Therapeutics is transforming drug discovery with computational chemistry and AI to design small molecules that precisely target disease. CEO Abbas Kazimi, who took the helm in March, is driving a “fail fast” approach that balances discipline with innovation. He joins Inside the ICE House to share how Nimbus is s
Michael Reinking, Senior Market Strategist for the NYSE, recaps a choppy week driven by tariff uncertainty, tech earnings misses, and focus on the upcoming jobs report. He notes August ended strong for small and mid-caps, but September’s seasonal weakness and rising global yields remain risks. Labor data showed slower
Biotech Series: Eli Lilly Chief AI Officer Thomas Fuchs on AI's Power to Transform Pharmaceuticals
AI is revolutionizing pharmaceuticals, moving from a side tool to a core driver of many aspects of the industry. Eli Lilly is leading the way, appointing Thomas Fuchs as its first Chief AI Officer to integrate AI across its pipeline. A NASA and Mount Sinai veteran, Fuchs is turning Lilly’s data into a competitive edge.
Alex Zweber, Portfolio Manager and Strategist at Parametric under Morgan Stanley Investment Management, joins Bilal Little, Director of Exchange Traded Products at the NYSE, to share his journey from derivatives trading to leading Parametrics' liquid alternatives team. He discusses the explosive growth of ETFs for inco
